Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber management teams building world-class companies. Since 1973, Abingworth has invested in over 180 life science companies, leading to 46 M&As and 70+ IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. Abingworth became part of Carlyle (NASDAQ: CG) on 1 August 2022. 

X4 Pharmaceuticals

Zogenix

Personalis

GenSight Biologics

Alnylam Pharmaceuticals

Amarin

Phathom Pharmaceuticals

Avedro

Jasper Therapeutics

CRISPR Therapeutics

Dicerna Pharmaceuticals

Senseonics

Effector Therapeutics

Sientra

Spruce Biosciences

Vaxcyte

Vera Therapeutics

Verona Pharma

Abingworth

Abingworth LLP (formerly Abingworth Management Ltd.) is a transatlantic bioscience investment firm that has been investing in life science and healthcare services companies since the early days of the biotechnology industry. The company has helped young biopharma companies on both sides of the Atlantic turn scientific discoveries into new treatments for patients.

Abingworth LLP

COM:ABINGWORTH

Abingworth LLP

Filings Not Available